Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Non-Haematological Cancers – The Current Clinical Trials, Clinical Scenario, Pipeline Review and strategic alliance in schizophrenia

Monday, October 17, 2016 3:30
% of readers think this story is Fact. Add your two cents.

(Before It's News)

In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis, non-haematological cancers are thought to account for 94% of global cancer prevalence. The major cancer indications of this report, namely – breast, lung, colorectal and prostate cancer, constitute approximately 51% of global cancer prevalence.

Browse more detail information about Non-Haematological Cancers market:


The risk of cancer is found to be increased greatly in patients over the age of 65. As populations are projected to increase, with aging and increasing incidence of obesity, the prevalence of cancer as a genetic disease is only expected to increase, thereby acting as a driver for revenue growth.  Typically, chemotherapy has curative or palliative uses depending on whether the patient’s tumours are respectable or unrespectable, respectively; however, use of chemotherapies is often reliant on performance status, which is lacking in many cancer patients.


Get a PDF Sample of Non-Haematological Cancers market:


Scope Non-Haematological Cancers market:

Global revenues for the non-haematological cancer market are forecast to grow at a Compound Annual Growth Rate (CAGR) of 9.86%, from $73 billion in 2014 to $141 billion in 2021

What is the generic penetration?

Which drugs are going to achieve blockbuster status?


Overall, there are 6,484 oncology products in the pipeline, which make it the largest therapy area pipeline

How can the composition of the pipeline be compared with that of the existing industry?

What mechanisms of action are most prevalent for pipeline drugs?


18 of the top 20 pharmaceutical companies will market non-haematological cancer drugs in the forecast period

How is their revenue share of the non-haematological cancer market set to change?

What CAGR will these companies register for the forecast period?


Get Discount on Non-Haematological Cancers market:

Reasons to buy Non-Haematological Cancers market:

This report will allow you to:

Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options that are available at each stage of diagnosis

Visualize the composition of the non-haematological cancer market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players

Analyse the non-haematological cancer pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications

Understand the growth in patient epidemiology and market revenues for the non-haematological cancer market globally and across the key players and product types

Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various non-haematological cancers

Identify commercial non-haematological cancer opportunities deals landscape by analysing trends in licensing and co-development deals


Have any query? ask our expert @

List of Figures, Tables and Charts Available in Global Non-Haematological Cancers Market to 2021 – Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics

1.1 List of Tables

Table 1: Oncology, Global, Symptoms of Most Prevalent Non-haematological Cancers, 2015 10

Table 2: Complications Associated with Breast, Colorectal, Lung and Prostate Cancers 21

Table 3: Oncology, Global, Epidemiology of Most Prevalent Non-haematological Cancers, 2015 21

Table 4: Optimal and Actual Radiation Therapy Usage Rates, US, 1995-2000 27

Table 5: Optimal and Actual Chemotherapy Usage Rates, Australia, 2010 29

Table 6: Oncology Therapeutics Market, Global, Approved Indications for Avast in, 2015 34

Table 7: Oncology Therapeutics Market, Global, Approved Indications for Herceptin, 2015 36

Table 8: Oncology Therapeutics Market, Global, Approved Indications for Alimta, 2015 37

Table 9: Oncology Therapeutics Market, Global, Approved Indications for Zytiga, 2015 38

Table 10: Oncology Therapeutics Market, Global, Approved Indications for Xtandi, 2015 39About

Absolute Report:
Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in-depth market research. We are one of the top report resellers in the market dedicated towards bringing you an ingenious concoction of data parameters.

Mr. Ameya Pingaley

Absolute Reports
+1-408 520 9750
Get more market research related news @    

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.